Kidney Cancer

Data indicates that the DFS improvement was largely driven by the treatment effect in the higher risk population.

The median progression-free survival was 15.7 months with the combination of lenvatinib plus everolimus compared with 10.2 months with cabozantinib (HR, 0.51; 95% CI, 0.29-0.89; P = .02).

"Observed efficacy of pembrolizumab plus lenvatinib were confirmatory of prior observations for this combination," said Cristina Suarez Rodriguez, MD, PhD.

Data from the ARC-20 trial show promising efficacy and a manageable safety profile for casdatifan monotherapy.

Here’s a look back at notable news between July and September 2025.

This clearance adds onto a previous indication for the BioTraceIO platform in liver tumor ablation.

The combination also yielded durable responses in a subset of patients with sporadic papillary renal cell carcinoma.

Take a look through key stories from last month, including regulatory news, trial updates, and other practice-changing advancements.

Five-year data from the phase 3 KEYNOTE-426 trial confirm the clinical benefits of front-line pembrolizumab plus axitinib in advanced ccRCC.

MRWS was shown to prolong the time off systemic therapy and was associated with favorable tolerability.

A comprehensive guide to the key regulatory decisions and conferences slated for Q3 of 2025.

One key approach is to increase the representation of women on editorial boards of journals and as reviewers.

The combination of zanzalintinib plus nivolumab demonstrated encouraging preliminary activity with manageable safety.

Data from the #HOPE4KIDNEY trial is intended to support submission for regulatory clearance of the Edison Histotripsy System.

The new drug application is backed by data from the phase 2/3 FRUSICA-2 trial.

ORR in the zanzalintinib plus nivolumab arm was 63% (95% CI: 46-77) vs 40% (95% CI: 25-57) in the zanzalintinib plus nivolumab/relatlimab arm.

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of recurrence," says Naomi B. Haas, MD.

Campbell emphasized that although gender representation in medicine is shifting, structural and cultural biases continue to influence academic recognition.

The approvals are supported by findings from the phase 3 CheckMate-67T trial.

"Appropriate patient selection for CN is a highly individualized process that is improved with a multidisciplinary approach," write the authors.

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

The study was published in JCO Oncology Practice.

The website is meant to educate patients and their caregivers on several aspects of the kidney cancer journey.

Betty Wang, MD, provides insight on 3 presentations that she believes “may be game changing” in urology.